Temple Rock Holdings Inc.

CYNAPSUS ANNOUNCES POSITIVE PROOF OF CONCEPT RESULTS FOR PARKINSON'S DRUG CANDIDATE
TORONTO--(Marketwire - December 2, 2010) - Cynapsus Therapeutics Inc. ("Cynapsus") (formerly Cannasat Therapeutics Inc.) (TSX-V: CTH) is providing today an update on the progress of its research activities on its lead drug candidate, APL 130277, a potential treatment for patients with Parkinson's disease. MORE>>